Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
Portfolio Pulse from Benzinga Newsdesk
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) and Voyager Therapeutics, Inc. (NASDAQ:VYGR) have entered into a definitive license agreement for a potential treatment of prion disease. Sangamo has developed zinc finger transcriptional regulators (ZF-TRs) which can block expression of the prion protein. Voyager has provided Sangamo with access to a capsid derived from Voyager's proprietary TRACER™ platform.
June 29, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sangamo Therapeutics has entered into a license agreement with Voyager Therapeutics for a potential prion disease treatment. This could potentially boost Sangamo's product portfolio.
The license agreement with Voyager Therapeutics could potentially expand Sangamo's product portfolio and provide a new revenue stream. This could positively impact the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Voyager Therapeutics has entered into a license agreement with Sangamo Therapeutics for a potential prion disease treatment. This could potentially boost Voyager's product portfolio.
The license agreement with Sangamo Therapeutics could potentially expand Voyager's product portfolio and provide a new revenue stream. This could positively impact the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100